E. Smid

发表

18F-FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival.

B. Hoeben, C. Terhaard, J. Kaanders, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue.

P. Sminia, B. Slotman, P. Van Der Valk, 2006, Oncology reports.

Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration

S. Leenstra, P. Sminia, L. Stalpers, 2005, Journal of Cancer Research and Clinical Oncology.

Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer

R. de Bree, P. D. de Jong, A. Huitema, 2022, European Archives of Oto-Rhino-Laryngology.

The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy.

C. Leemans, E. Bloemena, B. Slotman, 2006, International journal of radiation oncology, biology, physics.

Combined therapy for thyroid squamous cell carcinoma

M. D. den Bakker, J. D. de Wilt, A. Sewnaik, 2012, Head and Neck.

Skeletal muscle mass measurements using head and neck CT imaging in head and neck cancer patients.

R. de Bree, I. Wegner, E. Smid, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Masseter muscle parameters can function as an alternative for skeletal muscle mass assessments on cross-sectional imaging at lumbar or cervical vertebral levels.

R. de Bree, J. Dankbaar, E. Smid, 2021, Quantitative imaging in medicine and surgery.

Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period.

H. Dehnad, L. Devriese, R. Bree, 2022, Brachytherapy.

Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.

R. de Bree, A. de Graeff, I. Wegner, 2017, Oral oncology.

Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma

R. de Bree, P. Doornaert, H. J. Smits, 2023, European Archives of Oto-Rhino-Laryngology.

Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score.

J. Verhoeff, C. Kleynen, C. Post, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Comprehensive Quantitative Evaluation of Inter-observer Delineation Performance of MR-guided Delineation of Oropharyngeal Gross Tumor Volumes and High-risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study

A. Garden, C. Fuller, I. Poon, 2022, medRxiv.

Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra

R. de Bree, F. Pameijer, G. Bol, 2019, European Archives of Oto-Rhino-Laryngology.

Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.

R. de Bree, W. Grolman, L. Leenen, 2016, Oral oncology.

Comprehensive Quantitative Evaluation of Variability in MR-guided Delineation of Oropharyngeal Gross Tumor Volumes and High-risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study.

A. Garden, C. Fuller, I. Poon, 2022, International journal of radiation oncology, biology, physics.

Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy

R. de Bree, P. D. de Jong, L. Devriese, 2021, Journal of clinical medicine.

Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.

R. de Bree, P. D. de Jong, G. Bol, 2021, Oral oncology.

Cut-off values for low skeletal muscle mass at the level of the third cervical vertebra (C3) in patients with head and neck cancer

R. de Bree, P. D. de Jong, E. Smid, 2021, Quantitative Imaging in Medicine and Surgery.

Arterial calcification on preoperative computed tomography imaging as a risk factor for pharyngocutaneous fistula formation after total laryngectomy

R. de Bree, P. D. de Jong, T. Pézier, 2021, Head & neck.

Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.

R. de Bree, A. de Graeff, I. Wegner, 2017, Oral oncology.

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

R. de Bree, M. Hendriks, C. V. van Gils, 2023, PloS one.